Dr. Lal PathLabs Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Dr. Lal PathLabs kazanç ve gelirin sırasıyla yıllık 14.8% ve 10.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 22.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.8%

Kazanç büyüme oranı

14.9%

EPS büyüme oranı

Healthcare kazanç büyümesi	27.3%
Gelir büyüme oranı	10.8%
Gelecekteki özkaynak getirisi	22.3%
Analist kapsamı	Good
Son güncelleme	31 Jan 2025

Gelecekteki son büyüme güncellemeleri

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Recent updates

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Jan 16

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jan 01

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

Kazanç ve Gelir Büyüme Tahminleri

NSEI:LALPATHLAB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	30,892	5,780	6,531	N/A	20
3/31/2026	27,652	5,004	5,737	N/A	21
3/31/2025	24,716	4,331	4,846	N/A	20
12/31/2024	24,042	4,168	N/A	N/A	N/A
9/30/2024	23,464	4,014	4,912	5,365	N/A
6/30/2024	22,875	3,815	N/A	N/A	N/A
3/31/2024	22,266	3,577	4,779	5,353	N/A
12/31/2023	21,722	3,298	N/A	N/A	N/A
9/30/2023	21,227	3,013	4,767	5,198	N/A
6/30/2023	20,552	2,638	N/A	N/A	N/A
3/31/2023	20,169	2,388	4,115	4,560	N/A
12/31/2022	20,114	2,435	N/A	N/A	N/A
9/30/2022	20,189	2,480	-824	3,884	N/A
6/30/2022	19,835	2,713	N/A	N/A	N/A
3/31/2022	20,874	3,448	-294	4,467	N/A
12/31/2021	20,329	3,669	N/A	N/A	N/A
9/30/2021	19,884	4,041	4,609	5,327	N/A
6/30/2021	19,219	3,944	N/A	N/A	N/A
3/31/2021	15,813	2,916	3,386	3,982	N/A
12/31/2020	14,520	2,407	N/A	N/A	N/A
9/30/2020	13,275	2,003	2,259	2,821	N/A
6/30/2020	12,612	1,955	N/A	N/A	N/A
3/31/2020	13,304	2,259	2,043	2,839	N/A
12/31/2019	13,298	2,405	N/A	N/A	N/A
9/30/2019	12,944	2,322	2,199	2,619	N/A
6/30/2019	12,463	2,086	N/A	N/A	N/A
3/31/2019	12,034	1,992	1,765	2,185	N/A
12/31/2018	11,691	1,923	N/A	N/A	N/A
9/30/2018	11,393	1,825	N/A	N/A	N/A
6/30/2018	10,999	1,761	N/A	N/A	N/A
3/31/2018	10,569	1,707	N/A	1,971	N/A
12/31/2017	10,100	1,617	N/A	N/A	N/A
9/30/2017	9,548	1,565	N/A	N/A	N/A
6/30/2017	9,389	1,586	N/A	N/A	N/A
3/31/2017	9,124	1,546	N/A	1,713	N/A
12/31/2016	8,902	1,576	N/A	N/A	N/A
9/30/2016	8,713	1,876	N/A	N/A	N/A
6/30/2016	8,249	1,413	N/A	N/A	N/A
3/31/2016	7,913	1,322	N/A	1,585	N/A
12/31/2015	7,654	1,201	N/A	N/A	N/A
3/31/2015	6,596	908	N/A	1,218	N/A
3/31/2014	5,579	763	N/A	980	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LALPATHLAB 'nin tahmini kazanç büyümesi (yıllık 14.8% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: LALPATHLAB şirketinin kazançlarının (yıllık 14.8% ) Indian pazarından (yıllık 17.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LALPATHLAB şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: LALPATHLAB şirketinin gelirinin (yıllık 10.8% ) Indian pazarından (yıllık 10.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LALPATHLAB şirketinin gelirinin (yıllık 10.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LALPATHLAB 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 22.3 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/31 20:48
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Dr. Lal PathLabs Limited 46 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Prashant Nair	Ambit Capital
Nitin Bhasin	Ambit Capital
null null	Antique Stockbroking Ltd.

Dr. Lal PathLabs Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Price target increased by 12% to ₹2,924

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Price target increased by 8.0% to ₹2,353

Price target increased by 7.2% to ₹2,091

Recent updates

Third quarter 2025 earnings: EPS misses analyst expectations

Dr. Lal Pathlabs Limited Approves Declaration Third Interim Dividend for Financial Year 2024-25

Dr. Lal PathLabs Limited to Report Q3, 2025 Results on Jan 30, 2025

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Non Executive Director recently sold ₹15m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹79m worth of stock

MD & Director recently sold ₹35m worth of stock

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Upcoming dividend of ₹6.00 per share

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

MD & Director recently sold ₹28m worth of stock

Price target increased by 12% to ₹2,924

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary